Τόμος 6 (1992) – Τεύχος 1 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 6 (1992) – Issue 1 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title

1. PHARMAKON Press Information Services, Athens, Greece

2. Professor of Physiology, Nursing Department, University of Athens, Athens, Greece

pharmakonpress[at]pharmakonpress[.]gr

2.       Howell, W.H., Holt, E.: Two new factors in blood coagulation: Heparin and pro-antithrombin. Am. J. Physiol. 47: 328-341 (1918)

3.       Rosenberg, R.D., Damus, P.S.: The purification and mechanism of action of human antithrombin-heparin cofact or. J. Biol. Chem. 248: 6490- 6505 (1973)

4.       Tollefsen, D.M., Blank, M.K.: Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J. Clin. Invest. 68: 589-596 (1981)

5.       Yin. E.T., Wessler. S., Butler, J.: Plasma heparin: a unique practical submigrogram sensitive assay. J. Lab. Clin. Med. 81: 298-310 (1973)

6.       Wessler. S.: Small doses of heparin and a new concept of hypercoagulability. Thromb. Diath. Haemor. 33: 81-86 (1974)

7.       Kakkar, V.V.: Low doses of heparin in the prevention of deep vein thrombosis. Schweiz. Akad. Med. Wiss. Bull. 29: 235-243 (1975)

8.       Kakkar. V.V., Corrigen. T.P., Fossard, D.P.: Prevention of fatal post-operative pulmonary embolism by low doses of heparin. An international muiticenter trial. Lancet 2: 45-51 (1975)

9.       Andersson, L.O., Barrowcliffe, T.W., Holmer, E., Johnson, E.A., Soderstrom, G.: Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X effect of heparin neutralization in plasma. Thromb. Res. 15: 531-541 (1979)

10.     Holmer, E., Kurachi, K., Söderström, G.: The molecular weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, iXa, XIa, XIIa and kallikrein by anti-thrombin. Bloch. J. 193: 395-400 (1981)

11.     Thomas, D.P., Merton, R.E., Lewis, W.E., Barrowcliffe, T.W.: Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb. Haemost. 45: 214-218 (1981)

12.     A. BIoom, D.P. Thomas (eds): Haemostasis and Thrombosis. Churchill Livingstone, New York, 1987

13.     M. Verstraete, J. Vermylen, R. Ljjnen, et al. (eds): Thrombosis and Haemostasis, Leuven University Press, Leuven, 1987

14.     Plessas, C.T., Plessas, S.T.: Antiplatelet drugs: Clinical pharmacology and pharmacokinetics. Epitheor. Klin. Farmakol. Farmakokinet. Int.Ed. 1: 5-22 (1987)

15.     Felez, J.: Biochemical aspects of the pathogenesis of venous thrombosis. Acta Chir. Scand. Suppl. 556: 9-17 (1990)

16.     Sikorski, J.M., Hampson, W.G., Staddon, G.E.: The natural history and etiology of deep vein throm-bosis after total hip replacement J. Bone Joint Surg. 63B: 171-177 (1981)

17.     Nemerson, Y., Furie, B.: Zymogena and cofactors of blood coagulation. CRC Crit.Rev.Biochem. 9: 45-85 (1980)

18.     Doolittle, R.F.: Fibrinogen and fibrin. Sci, Amer. 245(No6): 126-135 (1981)

19.     Pisano, J.J., Finlayson, J.S., Peyton, M.R. et al.: Epsilon-(gamma glutamyl)lysine in fibrin: lack of crosslink formation in Factor B deficiency. Proc. Natl. Acad. Sci. (Wash.) 68: 770-772 (1971)

20.     Collen, D., Rouvier, J., Chamone, D.A., Verstraete, M.: Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver. Eur. J. Clin. Invest. 8: 185-188 (1978)

21.     Suttie, J.W., Jackson, C.M.: Prothrombin structure, activation and biosynthesis. Physiol. Rev. 57: 1-70 (1977)

22.     Wilson, D.B., Salem, H.H., Mruk, J.S., Maruyama, I., Majerus, P.W.: Biosynthesis of coagulation factor V by a human hepatocellular carcinoma cell line. J. Clin. Invest 73: 654-658 (1984)

23.     Dahlback, B.: Human coagulation factor V purification and thrombin-catalyzed activation. J. Clin. Invest 66: 583-591 (1980)

24.     Kane, W.H., Lindhout, M.J., Jackson, C.M., Majerus, P.W.: Factor Va-dependent binding of factor Xa to human platelets. J. Biol. Chem. 255: 1170-1174 (1980)

25.     Altieri, D.C., Edgington, T.S.: The saturable hifh affinity association of factor X to ADP-stimulated monocytes defines a novel function. J. Biol. Chem. 263: 7007-7015 (1988)

26.     Drake, T.A., Ruf, W., Morrisey, J.H., Edgington, T.S.: Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J. Cell: Biol. 109: 389-395 (1989)

27.     Nemerson, Y.: Tissue factor and hemostasis. Blood 71: 1-8 (1988)

28.     Drake, T.A., Morrisey, J.H., Edgington, T.S.: Selective cellular expression of tissue factor in human tissues: implications for disorders of haemostasis and thrombosis. Am. J. Pathol. 143: 1087- 1097 (1989)

29.     Sugo, T., Ikari, N., Kato, H., Iwanaga, S., Fujii, S.: Functional sites of bovine high molecular weight kininogen as a cofactor in kaolin-mediated activation of factor XII (Hageman factor). Biochemistry 19: 3215-3220 (1980)

30.     Griffin, J.H., Cochrane, C.G.: Recent advances in the understanding of contact activation reactions. Semin. Thromb. Hemost. 5: 254-273 (1979)

31.     Murray, R.K.: Blood plasma and clotting. In Harper’s Biochemistry (R.K.Murray, D.K.Granner, P.A.Mayes, V.W.Rodwell. eds), 21^st Ed., pp. 607-617, Appleton and Lange, Norwalk, 1988

32.     Hemker, H.C.: In memory of François Josso. Why do hemophiliacs bleed? Scan. J. Haematol. 33 (Suppl.40): 11-19 (1984)

33.     Béguin.S., Hemker, H.C.,: Mode of action of enoxaparin in plasma. Acta Chir. Scand. Suppl. 556: 51-56 (1990)

34.     Hemker, H.C., Wielders, S., Béguin, S.: The thrombin potential in Fraxiparine. In: Fraxiparine, Second International Symposium, Recent Pharmacological and Clinical Data (H.Bounameaux, M.Samama, J.W.ten Cate, eds), p.89, Schat- tauer, Stuttgart, New York, 1990

35.     Esmon, C.T.: The regulation of natural anticoagulant pathways. Science 235: 1348-1352 (1987)

36.     Carrel, R.W., Cristey, P.B., Boswell, D.R.: Serpins: antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from aminoacid sequences. In: Ref. 14, p.1

37.     Tollefsen, D.M., Pestka, C.A., Monfafo, W.J.: Activation of heparin cofactor II by dermatan sulfate. J. Biol. Chem. 258: 6713-6716 (1983)

33.     Bjork, I., Danielson, A.: Antithrombin and related inhibitors of coagulation proteinases. In: Proteinase Inhibitors (A.J.Barrett, G.Salveson, eds), pp. 439-504, Elsevier Science Publishing Co., Inc., Amsterdam, 1986

39.     Barrowcliffe, T.W., Thomas, D.P.: Antithrombin III and heparin. In: Ref. 12, p. 849 (1987)

40.     Marcum, J.A., Rosenberg, R.D.: Anticoaguiantly active heparin sulfate proteoglycan and the vascular endothelium. Semin. Thromb. Hemost. 13: 464-474 (1987)

41.     Marlar, RA, Kleiss, A.J., Griffin, J.H.: Human protein C: inactivation of factor V and VIII in plasma by the activated molecule. Ann. N.Y. Acad. Sci. 370: 303-310 (1981)

42.     Gardiner, J.E., Griffin, J.H.: Human protein C and thromboembolic disease. Prog. Hematol. 13: 265-278 (1983)

43.     Kisiel, W.: Human plasma protein C: isolation, characterization and mechanism of activation by alpha-thrombin. J. Clin. Invest. 64: 761-769 (1979)

44.     Esmon, N.L., Owen, W.G., Esmon, C.T.: Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C, J. Biol. Chem. 257: 859-864 (1982)

45.     Comp, P.C.: Heparin-protein C interaction. Nouv. Rev. Fr. HSmatol. 26: 239-242 (1984)

46.     Kazama, Y., Niwa, M., Yamagishi, R., Takahashi, K., Sakuragawa, N., Koide, T.: Specificity of sulfated polysaccharides to accelerate the inhibition of activated protein C by protein C inhibitor. Thromb. Res. 48: 179-185 (1987)

47.     Hekman, C.M., Loskutoff, D.J.: Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch. Biochem. Biophys. 262: 199-210 (1988)

48.     Loskutoff, D.J., Sawdey, M., Mimuro, J.: Type 1 plasminogen activator inhibitor. Prog. Haemost. Thromb. 9: 87-115 (1989)

49.     Hart, P.H., Vitti, G.F., Burgess, D.R., Singleton, D.K., Hamilton, J.A.: Human monocytes can produce tissue-type plasminogen activator. J. Exp. Med. 169: 1509-1514 (1989)

50.     Blasi, F., Vasali, J.-D., Dano, K.: Urokinase-type plasminogen activator; proenzyme, receptor, and inhibitors. J. Cell. Biol. 104: 801-804 (1987)

51.     Miles, L.A., Plow, E.F.: Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb. Haemost. 58: 936-942 (1987)

52.     Plow, E.F., Freaney, D.E., PIescia, J., Miles, LA.: The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell. Biol. 103: 2411-2420 (1986)

53.     Kirchheimer, J.C., Remold, H.G.: Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 74: 1396-1402 (1989)

54.     Robinson, H.C., Honer, A.A., Hook, M., Ogren, S., Lindahl, U.: A proteoglycan form of heparin and its degradation to single chain molecules. J. Biol. Chem. 253: 6687-6693 (1978)

55.     Jaques, L.B.: Heparinsanionic polyelectrolyte drugs. Pharmacol. Rev. 31: 99-166 (1979)

56.     Casu, B.: Structure and biological activity of heparin. Adv. Carbohydr. Chem. Biochem. 43: 51-134 (1985)

57.     Jorpes, J.E., Bostrom, H., Mutt, V.: The linkage of the amino-group in heparin. J. Biol. Chem. 183: 607-612 (1950)

58.     Cifonelli, J.A.: The relationship of molecular weight and sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydr. Res. 37: 145-154 (1974)

59.     Danishefsky, I.: Synthesis and properties of heparin derivatives. Adv. Exper. Med. Biol. 52: 105-109 (1975)

60.     Lindahl, U., Hook, M., Backstrom, G., Jacobsson, I., Riesenfeld, J., Malmstrôm, A., Rodén, L., Feingold, D.S.: Structure and biosynthesis of hepartnllke polysaccharides. Fed. Proc. 36: 19-24 (1977)

61.     Jacobsson, I., Backstrôm, G., Hook, M., Lindahl, U., Feingold, D.S., Malmstrom, A., Rodén, L.: Biosynthesis of heparin: assay and properties of the microsomal uronosyl C-5 epîmerase. J. Biol. Chem. 254: 2975-2982 (1979)

62.     Choay, J., Lormeau, J.C., Petitou, M., Sinay, P., Fareed, J.: Structural studies on a biologically active hexasaccharide obtained from heparin. Ann. N.Y. Acad. Sci. 370: 644-649 (1981)

63.     Choay, J., Petitou, M., Lormeau, J.C., Sinay, P., Casu, B., Gatti, G.: Structure activity relationships in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem. Biophys. Res. Comm. 116: 492-499 (1983)

64.     Lindahl, U., Backstrom, G., Thunberg, L.: The anti-thrombin binding sequence in heparin. Identification of an essential 6-0-sulfate group. J. Biol. Chem. 258: 9826-9830 (1983)

65.     Atha, D.H., Stephens, A.W., Rosenberg, R.D.: Evaluation of critical groups required for the binding of heparin and antithrombin. Proc. Natl. Acad. Sci. USA 81: 1030-1034 (1984)

66.     Walenga, J.M., Petitou, M., Samama, M., Fareed, J., Choay, J.: Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. Thromb. Res. 52: 553-563 (1988)

67.     Casu, B., Petitou, M., Provasoli, M., Sinay, P.: Conformational flexibility: a new concept for explaining binding and biological properties of D-uronic acid containing glycosaminoglycans. TIBS 13: 221-225 (1988)

68.     Murray, R.K.: Glycoproteins and proteiglycans. In: See Ref. 31. p. 589, 1988

69.     Petitou, M., Duchaussoy, P., Lederman, I., Choay, J., Sinay, P., Jacquinet, J.C., Torri, G.: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide, a heparin having affinity for antithrombin Hi. Carbohydr. Res. 147: 221-236 (1986)

70.     Fareed, J., Kumar, A., Walenga, J.M., Emanuele, R.M., Williamson, K., Hoppensteadt, D.: Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv. Rev. Fr. H6matol. 26: 267-275 (1984)

71.     Fareed.J., Walenga, J.M., Hoppensteadt, D., Huan, X., Racanelli, A.: Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Haemostasis 18 (Suppl.3): 3-15 (1988)

72.     Linhardt, R.J., Loganathan, D., Al-Hakim, A., Wang, H,-M., Walenga, J.M., Hoppensteadt, D., Fareed, J.: Ollgisaccharide mapping of low molecular weight heparins: Structure and activity differences. J. Med. Chem. 33: 1639-1645 (1990)

73.     Kim, Y.S., Linhardt, R.J.: Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombin. Thromb. Res. 53: 55-71 (1989)

74.     Shiveley, J.E., Conrad, H.E.: Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 15: 3932-3942 (1976)

75.     Fusi, F.: U.S.Patent 4,281,108; July 28. 1981

76.     Mardiguian, J.: U.S.Patent 4,440,926; April 3, 1984

77.     Linhardt, R.J., Grant, A., Cooney, C.L., Langer, R.: Differential anticoagulant activity of heparin fragment prepared using microbial heparinase, J. Biol. Chem. 257: 7310-7313 (1982)

78.     Fareed, J., Walenga, J.M., Racanelli, A., Hoppensteadt, D., Huan, X.Q., Messmore, H.L.: Validity of the newly established low-molecular-weight heparin standard in cross-referencing low molecular weight heparins. Haemostasis 18 (Suppl.3): 33-47 (1988)

79.     Rosenberg, R.D: Heparin, antithrombin, and abnormal clotting. Annu. Rev. Med. 29: 367-378 (1978)

80.     Jordan, R.E., Beeler, D., Rosenberg, R.D.: Fractionation of low molecular weight heparin species and their interaction with antithrombin. J. Biol. Chem. 254: 2902-2913 (1979)

81.     Chang, J.A., Tran, T.H.: Antithrombin III Basel: identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J. Biol. Chem. 261: 1174-1176 (1986)

82.     Saba, H.I., Saba, S.R., Morelli, G.A.: Antiheparin activity in human endothelial cells. Thromb. Res. 42: 355-362 (1986)

83.     Owen, M.C., Borg, J.Y., Soria, C., Soria, J., Caen, J., Carrell, R.W.: Heparin binding defect in a new antithrombotic ill variant: Rouen, 47 to His. Blood 69: 1275-1279 (1987)

84.     Borg, J.Y., Owen, M.C., Soria, C., Soria, J., Caen, J., Carrell, R.W.: Proposed heparin binding site in antithrombin based on Arginine 47: a new variant Rouen-I! Arg to Ser. J. Clin, invest. 81: 1292-1296 (1988)

85.     Griffith, M.J.: Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin. Proc. Natl. Acad. Sci. USA 80: 5460-5464 (1983)

86.     Jordan, R.E., Oosta, G.M., Gardner, W.T., Rosenberg, R.D.: The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J. Biol. Chem. 225: 10081-10090 (1980)

87.     Hoylaerts, M., Owen, W.G., Collen, D.: Involvement of heparin chain length in the heparin catalyzed inhibition of thrombin by antithrombin III. J. Biol. Chem. 259: 5670-5677 (1984)

88.     Pletcher, C.H., Cunningham, M., Nelsestuen, G.L.: Kinetic analysis of various fractions and heparin substitutes in the thrombin inhibition reaction. Biochim. Biophys. Acta 838: 106-113 (1985)

89.     Oosta, G.M., Gardner, W.T., Beeler, D.L., Rosenberg, R.D.: Multiple functional domains of heparin molecule. Proc. Natl. Acad. Sci. USA 78: 829-833 (1981)

90.     Petitou,M.: Synthetic heparin fragments: new and efficient tools for study of heparin and its interactions. Nouv. Rev. Fr. H6matol. 26: 221-226 (1984)

91.     Ockelford, P., Carter, C.J., Cerskus, A., Smith, C.A., Hish, J.: Comparison of the in vivo haemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb. Res. 27: 679-690 (1982)

92.     Ofosu, F.A., Blajchman, M.A., Hirsh, J.: The Inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin III. Thromb. Res. 20: 391-403 (1980)

93.     Barrowcliffe, T.W., Merton, R.E., Havercroft, S,J., Thunberg, U., Thomas, D.P.: Low affinity heparin potentiates the action of high affinity heparin oligosaccharides. Thromb. Res. 34: 124-133 (1984)

94.     Rosenberg, R.D., Rellly, C., Fritze, L.: Atherogenic regulation by heparin-like molecules. Ann. N.Y. Acad. Sci. 454: 270-279 (1985)

95.     Bengtsson-Olivecrona, G, Ollvecrona, T.: Binding of active and inactive forms of lipoprotein lipase to heparin: effects of pH. Biochem. J. 226: 409-413 (1985)

96.     Zucker, M.G.: Heparin and platelet function. Fed. Proc. 36: 47-49 (1977)

97.     Barzu, T., Molho, P., Tobelem, G., Petitou, M., Caen, J.: Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta 845: 196-203 (1985)

98.     Hirsh, J.: Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis. Am. J. Surg. 161: 512-518 (1991)

99.     Carter, C.J., Kelton, J.G., Hirsh, J., Cerskus, A., Santos, A.V., Gent, M.: The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 59: 1239-1245 (1982)

100.   Cade, J.F., Buchanan, M.R., Boneu, B., Ockelford, P., Carter, C.J., Cerskus, A.L, Hirsh, J.: A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions. Thromb. Res. 35: 613-625 (1984)

101.   Ockelford, P.A., Carter, C.J., Mitchell, L., Hirsh, J.: Discordance between the anti-Xa activity and antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb. Res. 28: 401- 409 (1982)

102.   Van Ryn-McKenna, J., Ofosu, F.A., Hirsh, J., Buchanan, M.: Antithrombotic and bleeding effects of glycosaminoglycans with different degree of sulfation. Br. J. Haematol. 71: 265-269 (1989)

103.   Fareed, J., Wallenga, J., Kumar, A.: A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin. Thromb. Hemost. 11: 155-175 (1985)

104.   Weichert, W., Pauliks, V., Breddin, H.K.: Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs. Haemostasis 13: 61-71 (1983)

105.   Fareed, J., Wallenga, J., Williamson, K., Emanuele, R.M., Kumar, A., Hoppensteadt, D.A.: Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin. Thromb. Hemost. 11: 56-74 (1985)

106.   Breddin, K., Weichert, W., Krupinski, K.: New model of experimental thrombosis (laser) to approach the antithrombotic activity of CY 216. In: Fraxiparine, First International Symposium (K. Breddin, J. Fareed, M. Samama, eds), pp. 69-78, Schattauer, Stuttgart, New York, 1989

107.   Weichert, W., Breddin, K.: Effect of low molecular weight heparins on laser-induced thrombis formation in rat mesenteric vessels. Haemostasis 18 (Suppt.3): 55-63 (1988)

108.   Bender, N., Seidl, C., Weichert, W., Breddin, H.K.: Evaluation of the biological effects of low molecular weight heparins. Haemostasis 18: 23-32 (1988)

109.   Buchanan, M.R., Moneu, B., Ofosu, F., Hirsh, J.: The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin. Blood 65: 198-201 (1985)

110.   Wallenga, J.M., Petltou, M., Lormeau, J.C., Samama, M., Faree, J., Choay, J.: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challengers. Thromb. Res. 46: 187-198 (1987)

111.   Wallenga, J.M., Bara, L., Petitou, M., Samama, M., Fareed, J., Choay, J.: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole antifactor Xa activity. Thromb. Res. 51: 23-33 (1988)

112.   Thomas, D.P., Merton, R.E., Gray, E., Barrowcliffe, T.W.: The relative antithrombotic effectiveness of heparin, a low molecular weight heparin and a pentasaccharide fragment in an animal model. Thromb. Haemost. 61: 204-207 (1989)

113.   Ofosu, F.A., Smith, L.M., Anvari, N., Blajchman, M.A.: An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. Thromb. Haemost. 60: 193-198 (1988)

114.   Marciniak, E.: Factor Xa inactivation by antithrombin III: evidence for biological stabilization of factor Xa by factor V-phosphoiipid complex. Br. J. Haematol. 24: 391-400 (1973)

115.   Teitel, J.M., Rosenberg, R.D.: Protection of factor Xa from neutralization by heparin-antithrombin complex. J. Clin. Invest. 71: 1383-1391 (1983)

116.   Ofosu, F.A., Cerskus, A.L., Hirsh, J., Smith, L.M., Modi, G.J., Blajchman, M.A.: The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids and tisue factor. Br. J. Haematol. 57: 229-238 (1984)

117.   Verstraete, M.: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40: 498-530 (1990)

118.   Ofosu, F.A., Blajchman, M.A., Modi, G.J., Smith, L.M., Buchanan, M.R., Hirsh, J.: The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulfate, low molecular weight heparin and pentosan sulfate. Br. J. Haematol. 60: 695-704 (1985)

119.   Hemker, H.C.: The mode of action of heparin in plasma, in: Thrombosis and Haemostasis 1987 (XI^th Congress Brussels) (M. Verstraete, J. Vermylen, H.R. Lignen, et al., eds), pp. 17-36. Leuven University Press, Leuven, 1987

120.   Pieters, J., Lindhout, T.: The limited importance of factor Xa inhibition in the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 72: 2048-2052 (1988)

121.   Fernandez, F.A., Buchanan, M.R., Hirsh, J., Fenton, J., Ofosu, F.A.: Catalysis of thrombin inhibition provides an index for estimating antithrombotic potential of glycosaminoglycans in rabbits. Thromb. Haemost. 57: 286-293 (1987)

122.   Vairel, E.G., Brouty-Boye, H., Toulemonde, F., Doutremepuich, E., Marsh, N.A., Gaffrey, P.L.: Heparin and low molecular weight fractions enhance thrombolysis and by this pathway axercise a protective effect against thrombosis. Thromb. Res. 30: 219-224 (1983)

123.   Fareed, J., Wallenga, J.M., Hoppensteadt, D.A., Messmore, H.L.: Studies on the profibrinolytic actions of heparin and its fractions. Semin. Thromb. Hemost. 11: 119-207 (1985)

124.   Dosne, A.M., Bendetowcz, A.V., Kher, A., Samama, K.: Marked potentiation of plasminogenolytic activity of prourokinase by unfractionated heparin and a low molecular-weight heparin. Thromb. Res. 51: 627-63Q (1988)

125.   Doutremepuich, C., Toulemonde, F., Doutremepuich, F., de Seze, O., Bayrou, B., Pereira, F.: The t-PA like activity induced by heparin and a heparin fragment binds on experimental thrombin. Thromb. Res. 50: 335-338 (1988)

126.   Doutremepuich, C., de Haro, E., Doutrsmepuich, F., Lalanne, M.C., Toulemonde, F.: Kinetic study of t-PA release induced by heparin and heparin fragment. Thromb. Res. 53: 615-621 (1989)

127.   Faivre, R., Newhart, E., Mirshahi, M., Soria, C.: Fibrinolytic and thrombolytic parameters in patients with deep wein thrombosis treated by low molecular weight and standard heparin. Semin. Thromb. Hemost. 15: 435-439 (1989)

128.   Lourenco, D.M., Dosne, A.M., Kher, A., Samama, M.: Minimal effect of standard heparin and a low molecular weight heparin on the thrombolytic and fibrinogenolytic activity of scuPA in vitro. Thromb. Haemost. 62: 923-926 (1989)

129.   Omri, A.: Effects of unfractionated heparin and a low molecular weight heparin preparations on fibrinolysis in vitro study. Thromb. Haemost. 62: 510 (1989)

130.   Porta.R., Pescador, R., Niada, R., Diamantini, G., Fideli, G.L., Mantovani, M., Prino, G.: Profibrinolytic activities of chemically modified heparins with very low anticoagulant properties. Thromb. Res. 53: 435-445 (1989)

131.   Pradoni, P., Lensing, A.W.A., Detoni, R., Cogo, A., Cavona, G. et al.: Standard heparin and a low molecular weight heparin (CY 216) do not affect fibrinolysis in healthy volunteers. Throm. Haemost. 62: 508 (1989)

132.   Thomas, D.P., Merton, R.E., Barrowcliffe, T.W., Thunberg, L, Lindahl, U: Effects of heparin oligo-saccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb. Haemost. 47: 244-248 (1982)

133.   Barzu, T., Van Rijn, J.L.M.L., Petitou, M., Molho, P., Tobelem, G., Caen, J.P.: Endothelial binding sites for heparin specificity and role in heparinneutralization. Biochem. J. 238: 847-854 (1986)

134.   Sache, E., Maillard, M., Malazzi, P., Bertrand, H.: Partially desulfated heparin as a non-anticoagulant heparin: some physicochemical and biological properties. Thromb. Res. 55: 247-258 (1989)

135.   AndriuoIi.G., Mastacchi, R., Barbanti, M., Sarret, M.: Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 15: 324-330 (1985)

136.   Esquivel, C.O., Bergqvist, D., Bjork, C.G., Nilsson, B.: Comparison between the commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets In vivo. Thromb. Res. 28: 389-399 (1982)

137.   Diness, V., NieIsen, J.I., Pedersen, P.C., Wolffbrandt, K.H., Ostergaard, P.B.: A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin (LHN-1) and conventional heparin. Thromb. Haemost. 55: 410-414 (1986)

138.   Pangrazzi, J., Abbadini, M., Zameta, M., Naggi, A., Torri, G., Casu, B., Donati, M.B.: Antithrombotic and bleeding effects of a low molecular weight heparin fraction. Biochem. Pharmacol. 34: 3305- 3308 (1985)

139.   Salzman, E.W., Rosenberg, R.D., Smith, M.H., Lindon, J.N., Favreau, L.: Effect of heparin and heparin fractions on platelet aggregation. J. Clin. Invest. 65: 64-73 (1980)

140.   Brace, L.D., Fareed, J.: Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subtraction. Thromb. Res. 42: 762-782 (1986)

141.   Westwick, J., Scully, M.F., Poll, C., Kakkar, V.V.: Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb. Res. 42: 437-447 (1986)

142.   Ljungberg, B., Beving, H., Egberg, N., Johnsson, H., Versterqvist, O.: Immediate effects of heparin and LMW heparin on some platelets and endothelial derived factors. Thromb. Res. 51: 209-217 (1988)

143.   Horne, M.K., Chao, E.S.: The effect of molecular weight on heparin binding to platelets. Br. J. Haematol. 74: 306-312 (1990)

144. Eika, C.: Anticoagulant and platelet aggregating activities of heparin. Thromb. Res. 2: 349- (1973)

145.   Salzman, E.: Low-molecular-weight heparin: is small beautiful? N. Engl. J. Med. 315: 857-859 (1986)

146.   Barrett, P.A., Butler, K.D., Môrley, J., Page, C.P., Paul, W., White, A.M.: Inhibition by heparin of platelet accumulation in vivo. Thromb. Haemost. 51: 366-370 (1984)

147.   Brace, L., Fareed, J.: An objective assessment of interaction of heparin and its fraction with human platelts. Semin. Thromb. Hemost. 11: 190-198 (1985)

148.   Dunn, F.W., Soria, C., Thomaidis, A., Soria, J., Dupuy, E., Bellucci, S., Tobelem, G.: Interactions of platelets with standard heparin and low molecular weight fractions. Nouv. Rev: Fr. Heôatol. 26: 249-253 (1984)

149.   Mikhailidis.D.P., Barradas, M.A., Mikhailidis,A.M., Magnani,H., Dandona.P.: Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br. J. Clin. Pharmacol. 17: 43-48 (1984)

150.   Fernandez, F., Niguyen, P., Van Ryn, J., Ofosu, F.A, Hirsh, J., Buchanan, M.R.: Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb. Res. 43: 491-495 (1986)

151.   Blajchman, M.A., Young, E., Ofosu, F.A.: The effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann. N.Y. Acad. Sci. 556. 245-254 (1989)

152.   Lane, D.A., Denton, J., Flynn, A.M., Thunberg, L., Lindahl, U.: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem. J. 218: 725-732 (1984)

153.   Béguin, S., Undhout, T., Hemker, H.C.: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb. Haemost. 61: 25-29 (1989)

154.   Bell, W.R., Royall, R.M.: Heparin associated with thrombocytopenia: A comparison of 3 heparin preparations. N. Engl. J. Med. 303: 902-907 (1980)

155.   Kelton, J.G.: Heparin-induced thrombocytopenia. Haemostasis 16: 173-186 (1986)

156.   Mikhailidis, D.P., Barradas, M.A.: Low molecular weight heparin(oids): are they the answer to heparin-associated thrombocytopenia? J. Drug Develp. 1: 265-273 (1989)

157.   Rao, A.K., White, G.C., Sherman, L., Colman, R., Lan, G., Ball, A.P.: Low incidence of thrombocytopenia with porcine mucosal heparin. Arch. Int Med. 149: 1285-1288 (1989)

159.   Ellison, N., Edmunds, L.H.,Jr, Colman, R,W.: Pletelet aggregation following heparin and protamine administration. Anesthesiology 48: 65-68 (1978)

160.   Holmer.E., Soderberg, K.: Inhibition of heparin oligosaccharides by protamine chloride. Semin. Thromb. Hemost 11: 241-242 (1985)

161.   Hubbard, A.R., Jennings, C.A.: Neutralization of heparin sulfate and low molecular weight heparin by protamine. Thromb. Haemost 53: 86-89 (1985)

162.   Doutremepuich, C., Bonini, F., Toulemonde, F., Bertrand, H., Bertand, B.: In vivo neutralization of low molecular weight heparin fraction CY 216 by protamine. Semin. Thromb. Hemost. 11: 318-322 (1985)

163.   Diness, V., Ostergaard, P.B.: Neutraliszation of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats. Thromb. Haemost. 56: 318-322 (1986)

164.   Harenberg, J., Giese, Ch., Knodler, A., Zimmermann, R., Schettler, G.: Antagonisierung von niedermolekularem Heparin-Sandoz durch Protaminchlorid. Herz / Kreislauf 18: 578-581 (1986)

165.   Racanelli, A., Silber, I., Fareed, J.: Comparative time course of pharmacodynamic activity of low molecular weight heparin and heparin after protamine neutralization. Semin. Thromb. Hemost. 15: 386-389 (1989)

166.   Doutremepuich, C., de Harb, E., de Seze, O., Guyot, M., Bonini, F., et al.: In vivo and in vitro neutralization of low molecular weight fraction of heparin (CY 216) by protamine. In Fraxiparine: Analytical and Structural Data, Pharmacology, Clinical Trials (K.Breddin et al., eds), pp. 97-107, Schattauer Verlag, Stuttgart, 1989

167.   Olivecrona, T., Bengtsson, G., Marklung, S.E., Lindahl, U., Hook, M.: Heparin-lipoprotein interactions. Fed. Proc. 36: 60-65 (1977)

168.   Nilsson-Ehle, P., Garfinkel, A.A., Schotz, M.C.: Lipolytic enzymes and plasma lipoprotein metabolism. Ann. Rev. Biochem. 49: 667-693 (1980)

169.   Tansey, M.J.B., Opie, L.H.: Relation betwen plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet 1: 419-422 (1983)

170.   Hennan, N.E.: Heparin-induced hyperlipidemia in a patient with pre-existing dysbetalipoproteinemia. Clin. Pharm. 5: 761-764 (1982)

171.   Persson, E., Nilsson-Ehle, P.: Release of lipoprotein lipase and hepatic lipase activities. Effects of heparin and a low molecular weight heparin fragment. Scand. J. Clin. Lab. Invest. 50: 43-49 (1990)

172.   Schrader, J., Rieger, J., Müschen,H., Stibbe, W., Köstering, H., Kramer, P., Scheler, F.: Anwendung von niedermolekularem Heparin bei Haemodialysepatienten. Klin. Wochenschr. 63: 49-55 (1985)

173.   Persson, E., Nördenström, J., Nilsson-Ehle, P., Hagenfeldt, L.: Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur. J. Clin. Invest. 15: 215-220 (1985)

174.   Schrader, J., Kandt, M., Zürcher, C., Köstering, H., Scheler, F.: Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients. Haemostasis 16 (Suppl.2): 48-58 (1986)

175.   Schrader, J., Stibbe, W., Armstrong, V.W., Kandt, M., Muche, R., Köstering, H., Seidel, D., Scheler, F.: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int. 33: 890-896 (1988)

176.   Deuber, H.J., Schultz, W.: Wirkungen des in der Haemodialysebehandlung eingesetzten niedermolekularen Heparins auf das Blutbild und den Fettstoffwechsel nach 18 monatiger Therapie. Nieren-Hochdruckkr. 17: 161-266 (1988)

177.   Harenberg, J., Stehle, G., Dempfle, C.E., von Hodenberg, E., Heene, D.L.: Beeinflussung der Blutgerinnung und der Lipases durch das niedermolekulare Heparin CY 216. Arztl. Lab. 35: 73-79 (1989)

178.   Etienne, J., Millot, F., Pieron, R., Lamelle, P.: Release of LPL activity after intravenous injection of a low molecular weight heparin. Br. J. Clin. Pharmacol. 16: 712-714 (1983)

179.   Macintosh, F.C.: The biological standardization of heparin. Bul. Health Organ., League Nations 10: 144-154 (1943-1944)

180.   Thomas, D.P., Curtis, A.D., Barrowcliffe, T.W.: A collaborative study designed to establish the 4^th International Standard for Heparin. Thromb. Haemost 52: 148-153 (1984)

181.   Barrowcliffe, T.W., Curtis, A.D., Tomlinson, T.P., Hubbard, A.R., Johnson, E.A., Thoma, .D.P.: Standardization of low molecular weight heparins: A collaborative study. Thromb. Haemost. 54: 675-679 (1985)

182.   Barrowcliffe, T.W., Curtis, A.D., Johnson, E.A., Thomas, D.P.: An international standard for low molecular weight heparin. Thromb. Haemost 60: 1-7 (1988)

183.   Hemker, H.C.: A standard for low molecular weight heparin? Haemostasis 19: 1-4 (1989)

184.   Verstraete, M., Boogaerts: Haematological disorders. In: Avery’s Drug Treatment (T.M. Speight, ed), 3^rd Ed., pp. 958-1022, Adis Press, Auckland, 1987

185.   Lijnen, H.R., Van Hoef, B., Collen, D.: Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma. Thromb. Haemost. 51: 266-268 (1984)

186.   Tollefsen, D.M., Majerus, D.W., Blank, M.K.: Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257: 2162-2169 (1982)

187.   Tran, T.H., Marbet, G.A., Duckert, F.: Association of heriditary heparin co-factor II deficiency with thrombosis. Lancet 2: 413-414 (1985)

188.   Bjornsson, T.D., Wolfram, K.M., Kitchell, B.B.: Heparin kinetics determined by three methods. Clin. Pharmacol. Ther. 31: 104-113 (1982)

189.   Ofosu, F,A,: In vitro and ex vivo activities of CY 216: Comparison with other low molecular weight heparins. Haemostasis 20 (Suppl. 1): ISO- 192 (1990)

190.   Bjornsson, T.D.: Clinical pharmacology of heparin. Rec. Adv. Clin. Pharmacol. 3: 129-155 (1983)

191.   Estes, J.W.: Clinical pharmacokinetics of heparin. Clin. Pharmacokinet. 5: 204-220 (1980)

192.   Bjornsson, T.D.: Anticoagulants. In: Rational Therapeuticws (R.G. Williams, D.C. Brater, J. Mordenti, eds.), pp. 541-577, Marcel Dekker, New York, Basel, 1990

193.   De Swart, C.A.M., Nijmeyer, B., Roelofs, J.M.N., Sixma, J.J.: Kinetics of intravenously administered heparin in normal humans. Blood 60: 1251-1258 (1982)

194.   Boneu, B., Caranobe, C., Gabaig, A.M., Dupouy, D., Sie, P., Hirsh, J.: Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb. Res. 46: 835-844 (1987)

195.   Boneu, B., Caranobe, C., Sie, P: Pharmacokinetics of heparin and low molecular weight heparin. Baillteres Clin. Haematol. 3: 531-544 (1990)

196.   Harenberg, J., Stehle, G., Augustin, J., Zimmermann, B.: Comparative human pharmacology of low molecular weight heparins. Semin. Thromb. Hemost. 15: 414-423 (1989)

197.   Harenberg, J.: Pharmacology of low molecular weight heparins. Semin. Thromb. Hemost. 16 (Suppl.): 12-18 (1990)

198.   Bara, L., Samama, M.: Pharmacokinetics of low molecular weight heparins. Acta Chir. Scand. Suppl. 556: 57-61 (1990)

199.   Lormeau, J.C.: Physicochemical and biological characteristics of CY 216. In: Fraxiparine, First International Symposium (K. Breddin, J. Fareed, M. Samama, eds), p. 13, Schattauer, Stuttgart, New York, 1989

200.   Petitou, M.: Molecular basis for activity of CY 216. In: See ref. 199, p.6, 1989

201.   Merton, R.E., Thomas, D.P., Havercroft, S.J., Barrowcliffe, T.W., Lindahl, U.: High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs. Thromb. Haemost. 51: 254-256 (1984)

202.   Harenberg, J., Wurzner, B., Zimmermann, R., Schettler, G.: Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Throm. Res. 44: 549-554 (1986)

203.   Thomas, D.P.: Biologicals, standards and heparin. Thromb. Haemost. 62: 648-650 (1989)

204.   Daves, J., Prowse, C.V., Pepper, D.S.: Absorption of heparins, LMW heparin and SP 54 after subcutaneous injection, assessed by competitive binding assay. Thromb. Res. 44: 683-693 (1986)

205.   Goutable, C., Gabaig, A.M., Rostin ,M., et al. : Influence of renal failure on pharmacokinetics of CY 216. Fundam. Clin. Pharmacol. 3: 178 (1989)

206.   Forestier, F., Daffos, F., Rainaut, M., Toulemonde, F: Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb. Haemost. 57: 234 (1987)

207.   Lindhout, Th., Pieters, J., Beguin, S., Hemker, H.C.: The mode of action of CY 216 on thrombin generation in plasma. In: See Ref. 199, pp. 23-24, 1989

208.   Hoppensteadt, D., Breddin, K., Walenga, J.M., Bender, N., Fareed, J.: Relevance of Anti Xa, Anti IIa and other laboratory parameters to the clinical efficacy of Fraxiparin : preliminary results of European Fraxiparin study . In: See Ref. 199, pp. 111-120, 1989

209.   Nine, .J., Duroux, P.: Treatment of proximal deep venous thrombosis with the low molecular weight subcutaneous heparin (Fraxiparine) or unfractionated intravenous heparin. In: See Ref. 34, p. 63, 1990

210.   Stassen, J.M., Juhan-Vague, I., Alessi, M.C., De Cock, F., Collen, D.: Potentiation by heparin fragments of thrombosis induced with human tissue- type plasminogen activator or human singlechain urokinase-type plasminogen activator. Thromb. Haemost 58: 947-950 (1987)

211.   Boisseau, M.R., Freyburger, G., Dachay, J., et al. : Effect of CY 216 and standard heparin on hemorheological factors. In: See Ref. 34, p.125,   1990

212.   Heinrich, D., Gérg, T., Schulz, M.: Effects of unfractionated and fractionated heparin on platetet function. Haemostasis 18 (Suppl.3): 48-54 (1988)

213.   Potron, G.M., Choisy, H., Droulle, C.L., et al. : Prospective post marketing follow-up of Fraxiparine in Reims. In: See Ref. 199, p. 157, 1989

214.   Du roux, P.: Curative treatment of deep venous thrombosis (DVT): Fraxiparine versus non-fractionated heparin (NFH). A European multicentre trial. In: See Ref. 199, pp. 189-191, 1989

215.   Racanelli, A., Fareed, J., Walenga, J., Coyne, E.: Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Semin. Thromb. Hemost. 11: 176-189 (1985)

216.   Boneu, B., Buchanan, M.R., Caranobe, C., Gabaig, A.M., Dupouy, D., Sie, P., Hirsh, J.: The disappearance of low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb. Res. 46: 845-853 (1987)

217.   Bara, L., Billaud, E., Gramond, G., Kher, A., Samama M.: Comparative pharmacokinetcs of low molecular weight heparin (PK 10169) and un-fractionated heparin after intravenous and subcutaneous administration. Thromb. Res. 39: 631- 636 (1985)

218.   Bara, L., Billaud, E., Kher, A., Samama, M: Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin. Semin. Thromb. Hemost. 11: 316-317 (1985)

219.   Frydman, A., Bara, L, Leroux, Y., WoIer, M., Chauliac, F., Duchier, J., Samama, M.: The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg. J. Clin. Pharmacol. 28: 608-618 (1988)

220.   Daves, J., Bara, L., Billaud, E., Samama, M.: Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 16: 116-122 (1986)

221.   Williams, S.P., Barrowcliffe, T.W.: The effects of post heparin plasma lipases on anti-Xa clotting activity. Thromb. Res. 37: 371-377 (1985)

222.   Laforest, M.D., CoIas-Linhart, N., Gulraux-Vitaux, F., Bok, B., Bara, L., Samama, M., Martin, J., Imbault, F., Uzan, A.: Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after i.v. injection in normal volunteers. Thromb. Haemost. 62: 515 (1989)

223.   Forestier, F., Daffos, F., Capella-Pavlovsky, M.: Low molecular weight heparin (PK 10169 Clexane) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb. Res. 34: 557-569 (1984)

224.   Ostergaard, P., Matzsch, T., Bergqvist, D., Bergqvist, A., Hodson, S., et al. : Transplacental passage of a low molecular weight heparin as compared to standard heparin. Thromb. Haemost. 62: 515 (1989)

225.   Andrew, M., et al. : A dermatan sulfate-like anticoagulant in the fetal lamb after administration of PK 10169 (Enoxaparine) to the ewe. Thromb. Haemost. 54: 32 (1985)

226.   Béguin, S., Mardiguian, J., Lindhout, T., Hemker, H.C.: The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma. Thromb. Haemost. 61: 30-34 (1989)

227.   Lane,D.A., Peyler.G., Flynn,A.M., Thompson,E.A., LindahQI.U.: Neutralization of heparin-related saccharides by histidin rich glycoprotein and platelet factor 4. J. Biol. Chem. 261: 3980-3986 (1985)

228.   Van Ryn-McKenna, J., Cai, L., Ofosu, F.A., Hirsh, J., Buchanan, M.R.: Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb. Haemost. 63: 271-274 (1990)

229.   Bergqvist, D., Hedner, U., Sjorin, E., Holmer, E.: Anticoagulant effect of two types of low molecular weight heparin administrered subcutaneously. Thromb. Res. 32: 381-391 (1983)

230.   Bratt, G., Tornebohm, E., Lockner, D., Bergstrom, K.L.: A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb. Haemost. 53: 762-782 (1985)

231.   Bratt, G., Tornebohm, E., Widlung, L, Lockner, D.: Low molecular weight heparin (Kabi 2165, Frag-min): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb. Res. 42: 613-620 (1986)

232.   Lockner, D., Bratt, G., Tornebohm, E., Aberg, W., Granqvist, S.: Intravenous and subcutaneous administration of fragmin in deep venous thrombosis. Haemostasis 16 (Suppl.2): 25-29 (1986)

233.   Born, J.J.J., Krediet, R., Sturk, A., ten Cat, .J.W.: Heparin versus low molecular weight heparin Kabi 2165 on chronic hemodialysis patients: a randomized cross-over study. Haemostasis 16 (Suppl.2): 59-68 (1986)

234.   Knudsen, J.B., Torholm, C., Jorgensen, P.K., Hagen, K., Broeng, L. et al.: Effect on coagulation parameters of low molecular weight heparin (fragmin) in elective and acute hip surgery. Thromb. Haemost. 62: 523 (1989)

235.   De Boerk, K., Heyboer, H., ten Cate, J.W., Borm, J.J., van Ginkel, C.J.: Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoids. Thromb. Heamost. 61: 148 (1989)

236.   Harenberg, J., Leber, G., Zimmermann, R., Schmidt, W.: Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtshilfe Frauenhelld 47: 15-18 (1987)

237.   Matzsch, T., Bergqvist, D., Hedner, V., Nilsson, B., Ostergaard, P.: Effects of low molecular weight heparin on induction of osteoporosis in rats. Thromb. Haemost. 63: 505-509 (1990)

238.   Matzsch, T., Bergqvist, D., Hedner, V., Ostergaard, P.: Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb. Haemost. 57: 97-101 (1987)

239.   Johnston, R.V., Orr, M., Rumbley, A., et al.: A study of the anti-thrombotic potential of low molecular weight heparin LHN-1 (Novo) in normal volunteers. Thromb. Haemost. 58: 119 (1987)

240.   Pedersen, P.C., Ostergaard, P., Hedner, U., Bergqvist, D., Màtzsch, T.: Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb. Res. 61: 477-487 (1991)

241.   Omri, A., Delaloye, J.F., Andersen, H., Bachmann, F.: Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb. Haemost 61: 55-56 (1989)

242.   Hellstern, P., Kiehl, R., Von Blohn, G., Kohler, M., Meierhenrich, U., Wenzel, E.: Dose response relationship of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals. Thromb. Haemost. 56: 225-228 (1986)

243.   Stehle, G., Giese, C., Dempfle, C.E., Heene, D.L., Harenberg, J.: Subcutaneous administration of two high doses of a low molecular weight heparin for 8 days twice daily. Thromb. Haemost. 62: 514 (1989)

244.   Grimaudo, V., Omri, A., Kruithof, E.K., Hauert, J., Bachmann, F.: Fibrinolytic and anticoagulant activity after a single subcutaneous administration of low dose of heparin or a low molecular weight heparin. Thromb. Haemost. 59: 338-391 (1988)

245.   Eriksson, E., Wollter, I.M., Christenson, B., Stigendal, L., Risberg, B.: Heparin and fibrinolysis – comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb. Haemost. 59: 284-288 (1988)

246.   Yin, E.T., Wessler,S., Stoll, P.J.: Biological properties of naturally occurring antithrombotic and anticoagulant effect of low molecular weight heparin. Thromb. Res. 21: 169-174 (1981)

247.   Mascellani.P., Bianchini.P. (Opocrin SpA): Depolymerized hexaminoglucan sulfates endowed with an antithrombotic, fibrinolytic, antiinflammatory activity: their process of preparation and related pharmaceutical compositions. WO Patent 86/06729, 15 May, 1986

248.   Dettori,A.G., TagIiaferri,A., Dall’Aglio.E., Pini.M.: Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum). Int. Angiol. 7       (Suppl.3): 7-18 (1988)

249.   Hirsh, J., Hull, R.D.: Pathogenesis of venous thromboembolism and clinical risk factors. In: Venous Thromboembolism : Natural History, Diagnosis and Management (J. Hirsh, R.D. Hull. eds), CRC Press, Boca Raton, 1987

250.   G.D. Lund berg (ed.): Consensus Conference Prevention of venous thrombosis and pulmonary embolism. J. Am. Med. Assoc. 256: 744-749 (1986)

251.   Bergentz, S.E.: Incidence of thromboembolism in association with surgical and medical diseases. Acta Chir. Scand. Suppl. 543: 10-14 (1988)

252.   Kakkar, V.V., Nicolaides, A.N., Renney, J.T.G., Friend, J.R., Clarke ,M.B.: 125i-labelled fibrinogen test adapted for routine screening for deep vein thrombosis. Lancet i: 540-542 (1972)

253.   Lea Thomas, M.: Phlebography. Arch. Surg. 104: 145-151 (1972)

254.   Sigel, B., Felix, W.R., Popky, G.L., et al. : Diagnosis of lower limb venous thrombosis by Doppler ultrasound technique. Arch. Surg. 104: 174-179 (1972)

255.   Hull, R., Hirsh, J., Sackett, D., Ipsen, D.: Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N. Engl. J. Med. 296: 1497-1500 (1977)

256.   Hull, R., Hirsh, J., Carter, C., Jay, R.M., Dodd, P.E., Ockelford, PA, Coates, G., Gill, G.J., Turpie, A.G., Doyle, D.J., Buller, H.R., Raskob, G.E.: Pulmonary angiography, ventilation lung scanning and venography for clinical suspected pulmonary embolism with abnormal perfusion lung scan. Ann. Int. Med. 98: 891-899 (1983)

257.   Salzman.E.W., Hirsh,J.: Prevention of venous thromboembolism. In: Haemostasis and Thrombosis (R.W.Colman et al. eds), 2nd Ed., pp.

1252- 1265, JJ.Lippincott, Philadelphia, 1987

258.   D.Bergqvist (ed.): Postoperative Thromboembolism. Frequency, Aetiologty – Prophylaxis. Springer Verlag, Berlin, 1983

259.   Srulberg.B.N., Insall.J.N., Williams.G.W., Ghel- man,B.: Deep vein thrombosis following total knee replacement. Am. J. Bone Joint Surg. 66: 194-201 (1984)

260.   Sikorski.J.M., Hampson,W.G., Staddon.G.E.: The natural history of aetiology of deep vein thrombosis after hip replacement. Br. J. Bone Joint Surg. 63: 171-177 (1981)

261.   Hirsh,J.: Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. Acta Chir. Scand. Suppl. 556: 30-35 (1990)

262.   Salzman, E.W., Harris, W.H.: Prevention of venous thromboembolism in orthopaedic patients. Am. J. Bone Joint Surg. 58: 903-913 (1976)

263.   Le Brigand, H., Morille, P., Garnier, B., Bogaty-Yver, J., Samama, M., Spriet, A.: Essai de prévention des accidents thromboemboliques postopératoires par les faibles doses d’héparinate de calcium en chirurgie thoracique. Sem. Hôp. Paris 57: 972-977 (1981)

264.   Turpie.A.G.G., Gent.M., Doyle.D.J., Saerens.E., Doboer,A.C., Talbot,C., McNamee.H., Hirsh.J.: An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. Thromb. Res. 39: 173-181 (1985)

265.   Skillmann.J.J., Collins.R.E.C., Coe.N.P., Gold- stein.B.S., Shapiro.R.M., Zervas.N.T., Bett- mann.M.A., Sarzman.E.W.: Prevention of deep vein thrombosis in neurosurgical patients : a controlled, randomized trial of external pneu¬matic compression boots. Surgery 83: 354-358 (1978)

266.   Joffe.S.N.: Incidence of post operative deep vein thrombosis in neurosurgical patients. J. Neuro- surg. 42: 201-203 (1975)

267.   Wetzel,N., Anderson.M.C., Shields,T.W.: Pulmonary embolism as a cause of death in neurosurgical patient. J. Neurosurg. 17: 664-668 (1960)

268.   Watson, N.: Anticoagulant therapy in the treatment of venous thrombosis and pulmonary embolism in acute spinal injury. Paraplegia 12: 197-201 (1974)

269.   Masliah-Planchon, R., Lavigne, F., Claquin, Ch., Papierni, K.E.: Prévention systématiques des thromboses veineuses profondes par héparinothérapie souscutanée après césarienne. J. Gynécol. Obstét. Biol. Reprod. 12: 95-100 (1983)

270.   Rudigoz, R.C., Arnaud, M.F., Dargent, D., Magnin, P.: Le risque thromboembolique pendant la grossesse et le post-partum. J. Gynécol. Obstét. Biol: Reprod. 10: 155-161 (1981)

271.   Kottke.B.A.: Disorders of the blood vessels. In: Princioples and Practice of Geriatric Medicine (M.S.J.Pathy, ed.), pp.419-456 Wiley, Chichester, 1985

272.   Busby,W., Bayer,A., Pathy,J.: Pulmonary embolism in the elderly. Age Ageing 17: 20-69 (1988)

273.   Scurr.J.H., Coleridge-Smith.P.D., Hasty,J.H.: Deep venous thrombosis: A continuing problem. Br. Med. J 297: 6640 (1988)

275.   Collins,R., Scrimgeour.A., Yusuf,S., Peto,R.: Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overreview of results of randomized trials in general orthopedic and urologie surgery. N. Engl. J. Med. 318: 1162- 1163 (1988)

276.   Clagett, G.P., Reisch, J.S.: Prevention of venous thromboembolism in general surgical patients. Ann. Surg. 208: 227-240 (1988)

277.   Hirsh, J.: Heparin. N. Engl. J. Med. 324: 1564- 1574 (1991)

278.   Kakkar, V.V., Corrigan, T.P., Fossard, D.P.: Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 2: 45-51 (1975)

279.   Prevention of fatal postoperative pulmonary embolism by low doses of heparin: reappraisal of results on international Multicentre Trial. Lancet 1: 567-569 (1977)

280.   Lindblad.B.: Prophylaxis of postoperative thromboembolism with low dose heparin alone or in combination with dihydroergotamine. A review. Acta Chir. Scand. 154 (Suppl.543): 31-42 (1988)

281.   Chiu, H.M., Hirsh, J., Yung, W.L., Regoeczi, E., Gent, M.: Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49: 171- 184 (1977)

282.   Hull, R.D., Raskob, G.E., Hirsh, J., Ray, R.M., Leclerc, J.R., Geerts, W.H., Rosenbloom, D., Sackett, D.L., Anderson, C., Harrison, L., Gent, M.: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N. Engl. J. Med. 315: 1109-1114 (1986)

283.   Kakkar, V.V., Stamatakis, J.D., Bentley, P.D., Lawrence, D., de Haas, H.A., Ward, V.P.: Prophylaxis of post-operative deep venous thrombosis: synergistic effect of heparin and dihydroergotamine. J. Am. Med. Assoc. 241: 39-42 (1979)

284.   Low.J., Biggs, J.C.: Comparative plasma heparin levels after subcutaneous sodium and calcium heparin. Thromb. Haemost 40: 397-406 (1978)

285.   Oshima.G.: Effects of different heparins on the enhancement of the trombin-antithrombin reaction. Biol. Chem. Hoppe-Seyler 371: 37-42 (1990)

286.   Beard,J.M., Rincon,F., Nacache, J.P., Chastang, C.: Tolérance locale de l’héparine sous-cutanée : comparaison en double insu de deux sels de calcium et de sodium. Sem. Hôp. Paris 55: 45-49 (1979)

287.   Kakkar, V.V., Murray, W.J.G.: Efficacy and safety of low molecular weight heparin (CY 216) in preventing postoperative venous thromboembolism : a cooperative study. Br. J. Surg. 72: 786-791 (1985)

288.   European Fraxiparine Study (EFS) Group : Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thromosis in patients undergoing abdominal surgery. Br. J. Surg. 75: 1058-1063 (1988)

289.   Bounameaux, H.: Low molecular weight heparins and prevention of postoperative thrombosis. Br. J. Surg. 76: 524 (1989)

290.   Pezzuoli,G., Neri Serneri,G.G., Settembrini, P.G., Coggi, G., Olivari, N., Negri, G., Codemo,R., Calli, G., Roveri,S.: Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, and controlled clinical trial versus placebo (STEP). Step Study Group. Haemostasis 20 (Suppl.1): 193-204 (1990)

291.   Besson,L., Azzar,D., Davidas,J.L., Massignon,D.,Rondelet,B., Banslllon,V., Dejour,H.: Efficacy and safety of CY 216 in the prevention of deep venous thrombosis after total hip replacement. In: See Ref. 199, pp. 127-133, 1989

292.   Simon, P., Kindermans, A., Kempf, J.F., Postel, M.: Efficacité et tolérance d’une héparine de bas poids moleculaire dans la prévention des thromboses profondes lors des arthroplasties totales de hanche reglées. Essai prospectif, multicentrique. J. Chir. (Paris) 127: 252-257 (1990)

293.   Leyvraz,P.F., Bachmann.F., Hoek,J., BüIler,H.R., Postel,M., Samama,M., Vandenbroek,M.D.: Prevention of deep vein thrombosis after hip replacement : Randomised comparison between unfractionated heparin and low molecular weight heparin. Br. Med. J. 303: 543-548 (1991)

294.   Paoletti, C., Maubec, E., Raggueneau, J.L., George, B., Robine, D., Matheron, R., Cophignon, J., Rey, A.: Etude de la tolerance clinique du CY 216D (Fraxiparine) dans la prevention des accidents thromboemboliques au decours de la neurochirurgre. Aggressologie 30: 363-366 (1989)

295.   Dahan.M., Boneu,M., Renella.J., et al.: Prevention of deep venous thrombosis in cancer thoracic surgery with a low molecular weight heparin Fraxiparine : comparative randomized trial. In: See Ref. 34, p. 27, 1990

296.   Morin,Y., Limon,S.: Utility and tolerance of CY 216 In the prevention of venous thrombosis in ophthalmic surgery. See Ref. 291, p. 135, 1989

297.   Clement,H.J., Caffin.J.P., Cortey.C.: Prévention des complications thromboemboliques après cé-sariennes : Résultats d’une enquête réalisée auprès des maternités de la Region Rhone- Alpes sur 3826 cesariennes realisees en 2 ans (1986-1987). Rev. Fr. Gynôcoi. Obstêt. 85: 114- 117 (1990)

298.   Samama, M., Combe, S.: Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane). Acta Chir. Scand, Suppl. 556: 91-95 (1990)

299.   Turpie,A.G.G., Levine,M.N., Hirsh,J., Carter,C.J., Jay,R.M., Powers,P.J., Andrew.M., Hull,R.D., Gent,M.: A randomized controlled trial of low molecular weight heparin (enoxaparine) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N. Engl. J. Med. 315: 925-929 (1986)

300.   Planes,A., Vochelle,N., Mazas.F., Mansat.C., Zucman,J., Landais,A., Pascariello, J.C., Weill,D., Butel,J.: Prevention of postoperative venous trhombosis : a randomized trial comparing un-fractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb. Haemost. 60: 407-410 (1988)

301.   Borris, LC., Hauch, O., Jorgensen,L.N., et al. : Enoxaparin versus dextran 70 in the prevention of postoperative deep vein thrombosis after totai hip replacement – a Danish Muiticentre Study. Proc. Danish Enoxaparin Symposium, February 3, 1990

302.   Koller,M., Schoch,U., Buchmann,P., Largiader,F., von Felten,A., Frick,P.G.: Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb. Haemost. 56: 243-246 (1986)

303.   Bergqvist,D., Burmark.U.S., Frisell,J., Hallbôôk,T., Lindblad,B., Risberg,B., Torngren,S., Wallin,G.: Low molecular weight heparin once daily compared with conventional low dose heparine twice daily. A prospective double blind multicentre trial on prevention of postoperative thrombosis. Br. J. Surg. 73: 204-208 (1986)

304.   Caen, J.A.: A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. Thromb. Haemost. 59: 216-220 (1988)

305.   Bergqvist, D., Matzsch, T., Burmark, U.S., Frisell, J., Guilbaud, O., Hallbook, T., Horn, A., Lindhagen, A., Ljungner, H., Ljungstrom, K.G., Onarheim, H., Risberg, B., Torngren, S., Ortenwall, P.: Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in prevention of thrombosis. Br. J. Surg. 75: 888-891 (1988)

306.   Fricker,J.-P., Vergnes, Y., Schach, A., Heitz,A., Eber,M., Grunebaum,L., Wiesel,M.L., Kher,A., Barbier,P., Cazenave,J.P.: Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Bur. J. Clin. Invest 18: 561-567 (1988)

307.   Hartl, P., Brücke, P., Dienst, E., Vinazzer, H.: Prophylaxis of thromboembolism in general surgery : comparison between standard heparin and fragmin. Thromb. Res. 57: 577-584 (1990)

308.   Barre, J., Pfister, G., Potron, G., Droulle, C., Baudrillard, J.C., Barbier, P., Kher, A.: Efficacité et tolerance comparée du Kabi 2165 et de l’heparine standard dans la prévention des trhomboses velneuses profondes au cours des protheses totales de hanche. J. Mai. Vase. 12 (Suppl. B): 90-95 (1987)

309.   Dechavanne, M., Ville, D., Berruyer, M., Trepo, F., Dalery, F., Clermont, N., Lerat, J.L., Moyen, B., Fischer, L.P., Kher, A., Barbier, P.: Randomized trial of a low molecular weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep vein thrombosis after elective hip surgery. Haemostasis 19: 5-12 (1989)

310.   Leyvraz, P.F., Richard, J., Bachmann, F., van Melle, G., Treyvaud, J.M., Livio, J.J., Candardjis, G.: Adjusted versus fixed subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N. Engl. J. Med. 309: 954-958 (1983)

311.   Eriksson, B.I., Zachrisson, B.E., Teger-Nilsson, A.-C., Risberg, B.: Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br. J. Surg. 75: 1053-1057 (1988)

312.   Liezorovicz, A., Picolet, H., Peyrieux, J.C., Boissel, J.P., H.B.P.M. Research Group: Prevention of perioperative deep vein thrombosis in general surgery : a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br. J. Surg. 78: 412-416 (1991)

313.   Matzsch, T., Bergqvist, D., Fred in, H., Hedner, U.: Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir. Scand. 156: 445-450 (1990)

314.   Matzsch, T., Bergqvist, D., Fredin, H., Hedner, U., Lindhagen A., Nistor, L.: Comparison of trhompoprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement. Thromb. Haemorrh. Disorders 3: 25-29 (1991)

315.   Lassen, M.R., Borris, L.S., Christiansen, H.M., Boll, K.L., Eiskjaer, S.P., Nielsen, B.W., Schott, P., Olsen.A.D., Rodenberg, J.C., Lucht, U.: Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop. Scand. 62: 33-38 (1991)

316.   Green, D., Lee, M.Y., Lim, A.C., Chmiel, J.S., Vetter, M., Pang, T., Chen, D., Fenton, L., Yarkony, G.M., Meyer, P.R., Jr: Prevention of thromboembolism after spinal cord injury using low- molecular-weight heparin. Ann. Int. Med. 113: 571-574 (1990)

317.   Adolf, J., Knee, H., Roder, J.D., van de Flierdt, E., Siewert, J.R.: Thromboembolie-prophylaxe mit niedermolekularem Heparin in der Abdominalchirurgie. Deutsch. Med. Woch. 114: 48-53 (1989)

318.   Kruck, M., Heilmann, L.: Low molecular weight heparin after major gynecologic operations: clinical results. Thromb. Haemost. 62: 489 (1989)

319.   Korninger, C., Schlag, G., Poigenfürst, J., Wilting, C., Redl, H., et al.: Randomized trial of low molecular weight heparin (LMWH) versus low dose heparin/acenocoumarin (H/AC) in patients with hip fracture: thromboprophylactic effect and bleeding complications. Thromb. Haemost 62: 187 (1989)

320.   Wetzel, D., Stringer, M.D., Hedges, A.R., Parker, C.J., Kakkar, V.V., et al.: Fixed combinations of low molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of post-operative deep vein thrombosis. Thromb. Haemost. 62: 523 (1989)

321.   Haas, S., Stemberger, A., Fritsche, H.M., Welzel, D., Wolf, H., Lechner, F., Blumel, G.: Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arznmt-Forsch. 37: 839-843 (1987)

322.   Verardi.S., Córtese, F., Baroni, B., Boffo, V., Casciani, C.U.: II ruolo delPeparina basso peso molecolare nella prevenzione dela thrombosi venosa profonda postoperatoria. La nostra es¬peranza su 88 casi. G. Chir. 10: 674-678 (1989)

323.   Chiapuzzo, E., Orengo, G.B., Ottria, G., Chiapuzzo, Α., Palazzini, E., Fusillo, M.: The use of low molecular weight heparins for post-surgical deep vein thrombosis prevention in orthopaedic patients. J. Int. Med. Res. 16: 359-366 (1988)

324.   Schondorf, T.H., Weber, U.: Prevention of deep vein thrombosis in orthopedic surgery with the combination of low dose heparin plus either dihydroergotamine or dextran. Scand. J. Haematol. 36: 126-140 (1980)

325.   Aquino, J.P., Gambier, A., Ducros, J.J.: Prevention of thromboembolic accidents in elderly subjects with Fraxiparine. In: See Ref. 34, pp. 51-54, 1990

326.   Manciet, G., Vergnes, C., Vaissié, J.J., Boisseau,M.R.: A study on the efficacy and tolerance of Fraxiparine during long term therapy of the elderly. In: See Ref. 34, pp. 55-59, 1990

327.   Dahan, D., Houlbert, D., Caulin, C., Cusin, E., Viltart, C., et al.: Prevention of deep vein thrombosis in elderly patient by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 16: 159-164 (1986)

328.   Poniewierski, M., Barthels, M., Kuhn, M., Poliwoda, H.: Ueber die Wirksamheit niedermolekularem Heparins (Fragmin) in der Thromboembolieprophylaxe bei internistischen Patienten : ein Randomisierte Doppelblindstudie. Med. Klinik. 83: 241-245 (1988)

329.   Harenberg.J., Kallenbach, B., Martin,U., Dempfte, C.E., Zimmermann, R., et al.: Randomized controlled study of heparin and low molegular weight heparin for prevention of deep vein thrombosis in medical patients. Thromb. Res.: (1990)

330.   Pini, M., Pattachini, C., Quintavalla, R., Ροll, Τ., Megha, A., Tagliaferri, C., Manotti, C., Dettori, A.: Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis – a randomized clinical trial. Thromb. Haemost 64: 222-226 (1990)

331.   Cruickshank, M.K., Levine, M.N., Hirsh, J., Roberts, R., Siguenza, M.: A standard heparin nomogram for the management of heparin therapy. Arch. Intern. Med. 151: 333-337 (1991)

332.   A Collaborative European Multicentre Study: A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb. Haemost. 65: 251-256 (1991)

333.   Thery, C.L.: Treatment of pulmonary embolism with CY 216. In: See Ref. 34, p. 81, 1990

334.   Huet, Y., Janvier, G., Bendriss, P.H., Wrnnock, S., Dugrais, G., Freyburger, G., Boisseras, P.: Treatment of established venous thromboembolism with enoxaparin: preliminary report. Acta Chir. Scand. 556 (Suppl.): 116-120 (1990)

335.   Holm, H.A., Ly, B., Handeland, G.F., Abildgaard, U., Arnesen, K.E., Gottschalk, P., Hoeg, V., Aandahl, M., Haugen, Κ., Laerum, F. et al.: Subcutaneous heparin treatment of deep venous thrombosis : a comparison of unfractionated and low molecular weight heparin. Haemostasis 16 (Suppi.2): 30-37 (1986)

336.   Ireland, H., Lane, D.A., Curtis, J.R.: Objective assessment of heparin requirement for hemodialysis in man. J. Lab. Clin. Med. 103: 643-652 (1984)

337.   Lane, D.A., Ireland, H., Tew, C.J., Flynn, A., Curtis, J.R.: Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure. Acta Chir. Scand. 54 (Suppi.543): 101-104 (1988)

338.   Schrader, J., Andersson, L.O., Armstrong, V.W., Kundt, M., Stibbe, W., Scheler, F.: Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. Sem. Thromb. Hemost. 16 (Suppl.): 41-45 (1990)

339.   Dieval, J., Moriniere, P., Bayron, B., Rousel, B., Fournier, A. et al.: Dose-finding study of the low molecular weight heparin CY 216 in chronic haemodialysis. In: See Ref. 166, pp. 169-175, 1989

340.   Steinbach,G., Bosc.C., Caraman.P.L., et al.: Utilisation en hémodialyse et en hémofiltration du CY 216 (Fraxiparine) en bolus intraveineux, chez les patients insuffisants rénaux aigus et chroniques, avec et sans risques hémorragique. Néphrologie 11: 17-21 (1990)

341.   Schlegel, N., Macher, M.A., Hurtaud, M.F., et al.: The use of CY 216 in paediatric hemodialysis. In: See Ref. 199, p.177, 1989 342. Lane, D.A., Ireland, H., Flynn, A., Anastasiades, E., Curtis, J.R.: Haemodialysis with low molecular weight heparin: dosage requirements for the elimination of extracorporeal fibrin formation. Nephrol. Dialys. Transplant. 1: 179-187 (1986)

343.   Maurin, N., Kierdorf, H.: A low molecular weight heparin Fragmin in hemodialysis. Klin. Wochenschr. 66: 246-249 (1988)

344.   Bianchetti, M.G., Speck, S., Muller, R., Oetliker, O.H.: Einfache Koagulationspröphylaxe mit der niedermolekularen Heparin Enoxaparin in der paediatrischen Haemodialyse. Schweiz. Rundsch. Med. Prax. 79: 730-731 (1990)

345.   Ockelford, P.: Heparin 1986: indications and effective use. Drugs 31: 81-88 (1986)

346.   Landefeld, C.S., Cook, E.F., Flatley, M., Welsberg, M., Goldman, L.: Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am. J. Med. 82: 703-713 (1987)

347.   Levine, M.N., Hirsh, J., Kelton, J.G.: Heparin-induced bleeding. In: Heparin: Chemical Properties, Clinical Applications (DALane, U. Lindahl, eds) pp. 517-532, Edward Arnold, London, 1989

348.   Sethi, G.K., Copeland, J.G., Goldman, S., Moritz, T., Zadina, K, Henderson, W.G.: Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol. 15: 15-20 (1990)

349.   Prins, M.H., de Ottolander, G.J.H., Gelsema, R., et al.: Deep vein prophylaxis with a low molecular weight heparin (Kabi 2165) in stroke patients. Thromb. Haemost. 58: 117 (1987)

350.   Cola, C., Ansell, J.: Heparin-induced thrombocytopenia and arterial thrombosis : alternative therapies. Am. Heart J. 119: 368-374 (1990)

351.   Linde, N., Tsakiris, D.A., Vogt, A., Marbet, G.A.: Heparin induzierte Thrombozytopenie. Perspektiven in einem therapeutischen Dilema. Vasa 20: 157- 163 (1991)

352.   Bell, W.R.: Heparin-associated thrombocytopenia and thrombosis. J. Lab. Clin. Med. 111: 600-605 (1988)

353.   Leroy, J., Leclerc, M.H., Delahousse, B.: Treatment of heparin associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin. Thromb. Hemost. 11: 326-329 (1985)

354.   Ginsberg, J.S., Hirsh, J.: Use of anticoagulants during pregnancy. Chest 95 (Suppl.2): 156S- 160S (1989)

355.   Ginsberg, J.S., Kowalchuk, G., Hirsh, J., et al.: Heparin effect on bone density. Thromb. Haemost 64: 286-289 (1990)

356.   Mätzsch, T., Bergqvist, D., Hedner, U., Ostregaard, P.: Heparin-induced osteoporosis in rats. Thromb. Haemost. 56: 293-294 (1986)

357.   Curry, N., Bardana, E.J., Pirofsky, B.: Heparin sensitivity: Report of a case. Arch, intern. Med. 132: 744-745 (1973)

358.   White, R.W., Sadd, J.R., Nensel, R.E.: Thrombotic complications of heparin therapy : including six cases of heparin-induced skin necrosis. Ann. Surg. 190: 595-608 (1979)

359.   O’Kelly.R., Magee.F., McKenna,J.: Routine heparin therapy inhibits adrenal aldosterone production. J. Clin. Endocrinol. Metab. 56: 108-112 (1983)

360.   Sherman,R.A., Ruddy,M.C.: Suppression of aldosterone production by low-dose heparin. Am. J. Nephrol. 6: 165-168 (1986)